Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DE:DC4)
XETRA:DC4
Dexcom (DC4) Stock Price & Analysis
2 Followers
DC4 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€71.47 - €131.78
Previous Close€119.6
Volume264.00
Average Volume (3M)282.00
Market Cap
€46.20B
Enterprise Value€48.02B
Total Cash (Recent Filing)$566.30M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Jul 25, 2024EPS Estimate
€0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding397,683,837
10 Day Avg. Volume109
30 Day Avg. Volume282
Standard Deviation0.31
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)27.19
Price to Sales (P/S)45.98
Price to Cash Flow (P/CF)97.10
P/FCF Ratio150.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.26
Enterprise Value/Gross Profit20.98
Enterprise Value/Ebitda52.11
Forecast
1Y Price Target
€143.44Price Target Upside19.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Dexcom News
PremiumStock Analysis & Ideas
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDexCom's impressive quarterly revenue, which surpassed projections, coupled with raised revenue guidance, reflects the company's strong financial health and growth trajectory.
Market LeadershipDexCom's continuous glucose monitoring system holds a leading position in the booming worldwide CGM market, showcasing the company's dominance in this space.
Product LaunchThe much-anticipated US launch of Stelo, tailored for non-insulin users with features like a 15-day wear time, is poised to tap into new market segments and drive revenue growth.
Bears Say
Earnings GuidanceThe adjusted revenue guidance indicates a slight decrease from prior market consensus expectations.
Financial PerformanceGross Margin (GM%) contracted from the previous year and was below analyst expectations.
Product PerformanceApproximately 20% of sensors may not last for the full 15 days, 10% of these sensors may last less than 12 days.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.82% Insiders
35.18% Mutual Funds
50.96% Other Institutional Investors
11.05% Public Companies and
Individual Investors
DC4 FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was €71.47 and its highest was €131.78 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 25, 2024 which is in 62 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 25, 2024. The company reported €0.295 earnings per share for the quarter, beating the consensus estimate of €0.25 by €0.045.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is €0.36.
How many shares outstanding does Dexcom have?
Dexcom has 397,683,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of €0.295 in its last earnings report, beating expectations of €0.25. Following the earnings report the stock price went down -5.389%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 2B.
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€143.44 (19.93% Upside)
€143.44 (19.93% Upside)
Blogger Sentiment
Bullish
DE:DC4 Sentiment 83%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.56%
12-Months-Change
Fundamentals
Return on Equity
28.54%
Trailing 12-Months
Asset Growth
17.52%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DC4 Company Deck
---
DC4 Earnings Call
Q1 2024
0:00 / 0:00
---
DC4 Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DC4 Stock 12 Month Forecast
Average Price Target
€143.44
▲(19.93% Upside)
Technical Analysis
Dexcom
―
Abbott Laboratories
―
Medtronic
―
Tandem Diabetes Care
―
Intuitive Surgical
―
Best Analysts Covering DC4
1 Year
1 Year Success Rate
17/20 ratings generated profit
1 Year Average Return
+37.15%
reiterated a buy rating 29 days ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +37.15% per trade.
---